+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statins and cardioprotection--more than just lipid lowering?

Statins and cardioprotection--more than just lipid lowering?

Pharmacology and Therapeutics 122(1): 30-43

Lipid-lowering using HMG-CoA reductase inhibitors or statin therapy forms the cornerstone of medical therapy in the primary and secondary prevention of cardiovascular disease. In addition, to the improvements in lipid profile, the beneficial effects elicited by this class of drugs may be attributed to their diverse variety of non-lipid lowering pleiotropic effects, including improved endothelial function, reduced oxidative stress, less platelet adhesion, and increased atherosclerotic plaque stability. A less appreciated effect of statin therapy that has been reported in experimental studies is its cardioprotective effect with respect to its ability to directly protect the myocardium from the detrimental effects of acute ischaemia-reperfusion injury. In the current article we review the cardioprotective effects of statin therapy beyond serum lipid lowering, the underlying mechanisms involved and the potential implications for patients with coronary heart disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911698

Download citation: RISBibTeXText

PMID: 19318042

DOI: 10.1016/j.pharmthera.2009.01.002

Related references

Statins and cardiovascular diseases: The multiple effects of lipid-lowering therapy by statins. Atherosclerosis 153(1): 181-189, November, 2000

When statins alone are insufficient for lowering lipid levels. Efficacy and risks of lipid lowering combination therapies, in particular, that of statin-fibrate combination. Der Internist 40(12): 1338-1345, 2000

Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study –. Circulation Journal 78(10): 2512-2515, 2015

Lipid-lowering drugs and homocysteine. A comparison between statins and other lipid-lowering drugs. Atherosclerosis 172(1): 191-194, 2004

Non-lipid benefits from statins in hypercholesterolemic hypertensives Reduction of platelet and endothelial activation after aggressive lipid-lowering treatment with simvastatin. American Journal of Hypertension 13(4 Part 2): 248A, April, 2000

The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription. Leukemia and Lymphoma 58(5): 1172-1177, 2016

Are there potential non-lipid-lowering uses of statins?. Drugs 56(4): 517-522, 1998

Statins: much more than just a lipid-lowering therapy. Indian Heart Journal 56(3): 204-209, 2004

Effect of non lipid-lowering of statins. Zhongguo Xinyao yu Linchuang Zazhi 21(10): 618-621, 2002

Statins and lipid-lowering strategies in PD. Contributions to Nephrology 178: 106-110, 2012

Perioperative statins: more than lipid-lowering?. Cleveland Clinic Journal of Medicine 75(9): 654-662, 2008

Lipid lowering, statins and cancer. International Journal of Clinical Practice 60(9): 1022-1024, 2006

Lipid lowering: statins and the future. Heart 84 Suppl 1: I46-7; Discussion I50, 2000